October 25, 2018 – A new study published yesterday in the American Journal of Clinical Nutrition (AJCN) adds to the body of data demonstrating that bioactive compounds found in cocoa can keep the heart healthy —but two types of bioactives called flavanols and procyanidins behave differently in the body.
Healthy adults experienced improved blood vessel function along with improvements in blood pressure, arterial stiffness, and cholesterol after one month of once-daily consumption of an extract enriched in flavanols and procyanidins.
Only the group that consumed flavanols and procyanidins together experienced all benefits. The group that consumed the procyanidin-enriched extract only experienced a reduction in total cholesterol.
Consequently, improvements in blood vessel function, blood pressure, and arterial stiffness were shown to predominantly relate to the intake of flavanols, but not to the intake of the more abundant procyanidins and their gut microbiome-derived metabolites.
Bioactives are dietary compounds that can be beneficial to health. Comprised of two kinds of bioactives, namely flavanols and procyanidins, the cocoa flavanols present in cocoa have attracted considerable scientific attention in recent years. As both groups of compounds are also found in apples, grapes, berries, and some cereals and legumes, the use of cocoa extract as a model for flavanol- and procyanidin-containing foods is likely to generate insights relevant beyond cocoa. Multiple studies have shown that daily consumption of flavanols and procyanidins has led to improved blood pressure, cholesterol and the flexibility of blood vessels. But until now, it was less clear to what extent flavanols and procyanidins respectively contribute to the observed benefits, and whether or not they act synergistically. A paper published this week in AJCN by an international team of researchers, including scientists from Mars, Incorporated, is the first to begin to directly answer this question.
In a month-long randomized and double-blinded study, 45 healthy male adults were divided into three groups taking different amounts of flavanols and procyanidins to determine the effect of each on a range of cardiovascular endpoints. One group of participants consumed a cocoa extract containing 130 mg of a flavanol called (−)-epicatechin (pronounced “minus epicatechin”) as well as 560 mg of procyanidins. The second group took cocoa extract capsules delivering a nearly equivalent amount of procyanidins (540 mg), but only 20 mg of (−)-epicatechin. The third group took placebo capsules that were free of both flavanols and procyanidins, but otherwise nutritionally matched to the capsules consumed by the other two groups. Importantly, all capsules were matched for their methylxanthine (caffeine and theobromine) amounts.
“We were able to confirm previous findings related to cocoa flavanols, and we gained novel insights into the respective contributions of flavanols and procyanidins in the context of their cardiovascular effects in humans. We found that the flavanols, especially (−)-epicatechin, represent the bioactives primarily responsible for the beneficial vascular effects observed after cocoa flavanol intake,” said Christian Heiss, a clinical professor based at the University of Surrey and Surrey and Sussex Healthcare NHS Trust, and one of the researchers in the study. “Only the group taking 130 mg of (−)-epicatechin experienced both the acute and long-term beneficial effects related to flavanol and procyanidin intake.” Acute responses included improvements in the ability of blood vessels to dilate. Long-term responses included improvements in blood pressure and arterial stiffness. The groups taking either a placebo or the low-epicatechin capsules experienced no significant changes in any of the above endpoints. “Although procyanidins did not directly improve blood vessel dilation, blood pressure or arterial stiffness, their intake did have a beneficial effect on blood lipids”, continued Dr. Heiss. “Both groups taking capsules that contained procyanidins had a reduction in total cholesterol compared to the placebo control group after one month.”
This study also looked at what happens to flavanols and procyanidins after they are consumed and enter the body. The results confirmed findings from earlier investigations, showing that flavanols and procyanidins are broken down by the microbiota in the human gut, resulting in the formation of compounds called gamma-valerolactones. Although gamma-valerolactones were proposed to be bioactive, potentially involved in mediating the cardiovascular benefits observed following the intake of flavanols and procyanidins, this study could not provide evidence in support of this notion. Gamma-valerolactones appeared not be directly involved in mediating improvements in blood vessel dilation, blood pressure, and vascular stiffness, and thus appear not to be bioactive in the context of these cardiovascular effects. Procyanidins are more likely to have important indirect effects by protecting flavanols within a food during food processing as well as in the gastrointestinal tract from degradation and inactivation.
“Compared to other bioactives, we know quite a lot about cocoa flavanols today, but this study provides new and important insights,” said Dr. Heiss. “It is critical to understand how these bioactives interact with each other and with the human body, in order to create a comprehensive basis for evidence-based recommendations about how much of these compounds, or the foods that contain them, people should be consuming for health maintenance and disease risk reduction.”
“Mars has a long-term commitment to cocoa flavanol research, which started over 20 years ago,” noted Dr. Hagen Schroeter, Chief Science Officer of MARS Edge. “This research builds on a number of well-designed small and medium-scale clinical cocoa flavanol-centric studies that together demonstrate flavanols and procyanidins have cardiovascular health benefits. These comprehensive and collaborative studies range from synthetic chemistry, analytics, and epidemiology to human metabolism and pharmacokinetics. Our aim now in partnering in the multiyear COSMOS clinical trial is to investigate at scale whether the health benefits of flavanols can be generalized to the population at large.”
As we age, blood pressure, cholesterol, and stiffness of arteries increase. What is important is that they are each independently associated with an increased risk of cardiovascular disease and death. Consuming procyanidins and flavanols, like (−)-epicatechin, could therefore help people maintain their heart health. A five-year study in approximately 21,000 men and women across the U.S called COSMOS being run by Brigham and Women’s Hospital, an affiliate of Harvard Medical School, in Boston, MA, and the Fred Hutchinson Cancer Research Center in Seattle, WA hopes to definitively study this topic. The COSMOS study, or “COcoa Supplement and Multivitamin Outcomes Study”, now in its third year, is a large-scale, randomized, placebo-controlled, clinical dietary intervention trial testing the risks and benefits of supplemental cocoa extract (containing (−)-epicatechin and procyanidins) and a multivitamin in the primary prevention of cardiovascular disease and cancer. The primary outcomes of the study are heart attack, stroke, coronary revascularization, cancer and death.
The study was published in the American Journal of Clinical Nutrition and is freely available on their website here: https://academic.oup.com/ajcn/advance-article/doi/10.1093/ajcn/nqy229/5144478.
About Mars, Incorporated
Mars is a family-owned business with more than a century of history making diverse products and offering services for people and the pets people love. With over $35 billion in sales, the company is a global business that produces some of the world’s best-loved brands: M&M’s®, SNICKERS®, TWIX®, MILKY WAY®, DOVE®, PEDIGREE®, ROYAL CANIN®, WHISKAS®, EXTRA®, ORBIT®, 5™, SKITTLES®, UNCLE BEN’S®, MARS DRINKS and COCOAVIA®. Mars also provides veterinary health services that include BANFIELD® Pet Hospitals, Blue Pearl®, VCA® and Pet Partners™. Headquartered in McLean, VA, Mars operates in more than 80 countries. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire its more than 100,000 Associates to create value for all its partners and deliver growth they are proud of every day.
About Mars Center For Cocoa Health Science
For more than 20 years, and based on collaborating with a multidisciplinary group of international experts, Mars, Incorporated has been conducting comprehensive and innovative research with a network of scientific collaborators around the world to advance the understanding of cocoa flavanols and their potential health benefits for the purpose of improving human health. Building on two decades of research in cocoa flavanols, the Mars Center for Cocoa Health Science (MCCHS) was established in 2012 to pioneer, collaborate, and share data and information regarding our research in the context of this field. MCCHS provides an overview of the outcomes of our research, including direct access to some of our over 140 published peer-reviewed scientific papers, as well as videos, slides and other information that Mars, Incorporated and its collaborators have developed to advance cocoa flavanol understanding. For more information, please visit http://www.marscocoascience.com